Biocon Quarterly Results Q1 FY27

Biocon started FY27 with higher sales and profit. Its biosimilars and generics businesses grew, while its services business remained under pressure. 

• Revenue rose 10% to ₹4,336 crore.
• Reported profit increased to ₹141 crore.
• EBITDA grew 7% to ₹902 crore.
• EBITDA margin stayed unchanged at 21%.
• Biosimilars revenue grew 16% year-on-year.
• Generics revenue grew 21% year-on-year.

Yes. Biocon's revenue and reported profit were higher than in the same quarter last year.

Revenue from operations increased to ₹4,336 crore in Q1 FY27, compared with ₹3,942 crore in Q1 FY26. This was a 10% year-on-year increase.

Reported net profit increased sharply to ₹141 crore, compared with ₹31 crore a year earlier.

Here are the key numbers:

The results cover the quarter ended on 30 June 2026 and were approved by Biocon's board on 5 August 2026.

Biocon's biopharma business was the main growth driver in Q1 FY27.

Biopharma includes its biosimilars and generics businesses. Revenue from this business increased 17% year-on-year to ₹3,615 crore.

Generics recorded the fastest percentage growth at 21%. Biosimilars, which contributed a much larger amount of revenue, grew 16%.

The services business was the weak spot. Its revenue fell 16% to ₹736 crore from ₹875 crore.

Biosimilars revenue increased 16% to ₹2,855 crore in Q1 FY27.

Biocon said growth in North America was supported by recently launched biosimilars such as Bosaya and Aukelso. Its oncology portfolio also remained stable.

The company also commercialised generic liraglutide in the US. Biocon continued expanding its product reach across Europe and emerging markets during the period.

For an investor, this matters because biosimilars are Biocon's largest revenue business. Continued growth here can have a bigger effect on the company's overall results than growth in a much smaller business.

Reported net profit rose from ₹31 crore to ₹141 crore, which looks like a very large jump.

However, you should not judge a company only from one headline profit number. Exceptional items can make comparisons look unusually high or low.

Biocon's net profit before exceptional items was ₹145 crore in Q1 FY27, compared with ₹42 crore in Q1 FY26.

Profit before tax before exceptional items also increased 24% to ₹141 crore, from ₹114 crore.

This indicates that the improvement was not limited to the final reported profit number.

Yes. Biocon's EBITDA increased 7% to ₹902 crore, compared with ₹846 crore in Q1 FY26.

EBITDA gives you an idea of profit from business operations before interest, tax, depreciation, and amortisation.

However, the EBITDA margin stayed at 21% in both periods.

That means Biocon earned more EBITDA in rupee terms because its business became larger, but the EBITDA earned on every ₹100 of revenue did not materially improve.

Do not decide whether a stock is good or bad from one quarter alone.

For Biocon, you can track these numbers over the next few quarters:

• Biosimilars sales continue growing across markets.
• Generics maintain their current growth momentum.
• Services business starts showing revenue recovery.
• EBITDA margin improves from current levels.
• Interest costs continue moving lower gradually.
• R&D investments lead to product launches.

Also check the company's valuation, cash flows, debt, regulatory risks, competition, and business outlook.

A company can report good results and still have an expensive stock price. Similarly, weak quarterly numbers do not automatically mean a business has become poor.

Biocon's Q1 FY27 numbers show improvement in its main businesses. Revenue from operations rose 10% to ₹4,336 crore, while reported net profit increased to ₹141 crore. Biosimilars and generics grew by 16% and 21%, respectively. EBITDA rose 7%, though its margin stayed at 21%. The main concern was the 16% fall in services revenue. Investors should watch whether biopharma growth continues and whether the services business recovers in the coming quarters.